Venetoclax salvage therapy in relapsed/refractory multiple myeloma

被引：3

作者：

Steinhardt, Maximilian J. ^{[1
]}

Truger, Marietta ^{[2
]}

Bittrich, Max ^{[1
]}

Zhou, Xiang ^{[1
]}

Noderer, Julia ^{[1
]}

Riedhammer, Christine ^{[1
]}

Xiao, Xianghui ^{[1
]}

Gawlas, Sophia ^{[1
]}

Weis, Philipp ^{[1
]}

Eisele, Florian ^{[1
]}

Haferlach, Claudia ^{[2
]}

Mersi, Julia ^{[1
]}

Waldschmidt, Johannes ^{[1
]}

Einsele, Hermann ^{[1
]}

Rasche, Leo ^{[1
,3
]}

Kortuem, K. Martin ^{[1
]}

机构：

[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] MLL Munich Leukemia Lab, Munich, Germany

[3] Univ Klinikum Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany

来源：

HAEMATOLOGICA | 2024年 / 109卷 / 03期

关键词：

DEXAMETHASONE; COMBINATION;

D O I：

10.3324/haematol.2023.283472

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：979 / 981

页数：3

共 50 条

[31] Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients
Min, Chao
Zhong, Xiong
Cui, Yue
Zhang, Hanfu
Wang, Qingming
FRONTIERS IN PHARMACOLOGY, 2025, 16
[32] KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma
Alsouqi, Aseel
Khan, Muhammad
Dhakal, Binod
Du, Liping
Harrell, Shelton
Hari, Parameswaran
Cornell, Robert F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (08): : 526 - 535
[33] LENALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Okada, K.
Okamoto, Y.
Tsukamoto, T.
Sugiura, H.
Matsui, H.
Ueda, T.
Jo, T.
Onishi, T.
Kunitomi, A.
Ueda, Y.
ANNALS OF ONCOLOGY, 2013, 24
[34] NK cell therapy in relapsed refractory multiple myeloma
Roshandel, Elham
Ghaffari-Nazari, Haniyeh
Mohammadian, Mozhdeh
Salimi, Maryam
Abroun, Saeid
Mirfakhraie, Reza
Hajifathali, Abbas
CLINICAL IMMUNOLOGY, 2023, 246
[35] Bendamustine therapy for advanced relapsed/refractory multiple myeloma
Shkury, Eden
Geva, Mika
Avigdor, Abraham
Nevo, Lee
Magen, Hila
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S189 - S189
[36] Novel Therapies for Relapsed/Refractory Multiple Myeloma: How Can We Improve on "Salvage" Therapy?-Introduction
Jakubowiak, Andrzej
SEMINARS IN HEMATOLOGY, 2012, 49 (03) : S1 - S2
[37] Daratumumab as salvage therapy in relapsed/refractory multiple myeloma patients after allogeneic stem cell transplantation
Essmann, S.
von Pein, U. -M.
Klyuchnikov, E.
Janson, D.
Bonmann, S.
Ayuk, F. A.
Wolschke, C.
Kroeger, N.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 190 - 190
[38] Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
Papanikolaou, Xenofon
Szymonifka, Jackie
Rosenthal, Adam
Heuck, Christoph J.
Mitchell, Alan
Johann, Donald, Jr.
Keller, Jason
Waheed, Sarah
Usmani, Saad Z.
Van Rhee, Frits
Bailey, Clyde
Petty, Nathan
Hoering, Antje
Crowley, John
Barlogie, Bart
HAEMATOLOGICA, 2013, 98 (07) : 1147 - 1153
[39] Daratumumab as salvage therapy in relapsed/Refractory multiple myeloma patients after allogenic stem cell transplantation
Essmann, Sonja
von Pein, Ute-Marie
Klyuchnikov, Evgeny
Janson, Dietlinde
Bonmann, Stefan
Ayuk, Francis Ayuketang
Wolschke, Christine
Kroeger, Nicolaus
BONE MARROW TRANSPLANTATION, 2019, 54 : 496 - 496
[40] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Xiaohui Gao
Hui Zeng
Xiaoyan Zhao
Haibing Wu
Minchao Yan
Yuan Li
Gang Zhang
Fei Sun
BMC Cancer, 23

← 1 2 3 4 5 →